About US
Contact us
-
NovaSterilis awarded patent for sterilization process for pharmaceutical API using supercritical carbon dioxideNovaSterilis Inc., a developer of supercritical carbon dioxide technology, has been granted US Patent 8,012,414 B2. The patent, dated September 6, 2011 entitled “Sterilization of Drugs Using Supercrit2011/10/12
-
AstraZeneca to cut 400 US jobsAstraZeneca plans to cut 400 jobs in efforts to "streamline portions of its US commercial business." The job losses are planned for the company's US base in Delaware, although 70 of the 400 cuts will2011/10/12
-
FDA clears Merck type 2 diabetes medicationThe US Food and Drug Administration (FDA) has approved Merck's Juvisync, a once-daily therapy for type 2 diabetes that combines glucose-lowering medication sitagliptin, the active component of Januvia2011/10/12
-
AstraZeneca Faslodex wins Japanese regulatory approvalAstraZeneca has received Japanese regulatory approval for Faslodex (fulvestrant) 500mg, an oestrogen receptor antagonist for the treatment of postmenopausal women with hormone receptor-positive metast2011/9/30
-
Novartis reports positive results from breast cancer drug trialA Phase III study carried out by Novartis has demonstrated that Afinitor (everolimus) tablets coupled with exemestane can more than double the time women with breast cancer live without tumour growth.2011/9/30
-
SHL to Speak at the Upcoming Drug Delivery Trends Symposium in KoreaSHL marketing director Steven Kaufman will be speaking at the upcoming Primary Packaging and Drug Delivery Trends for Injectables symposium held by Pharmapack Symposium in Seoul, Korea on 14 October 22011/9/30
-
SFDA Commissioner Shao Mingli meets Deputy Minister of the Syrian Ministry of HealthOn the morning of September 23, 2011, Shao Mingli, Commissioner of the State Food and Drug Administration (SFDA) met with the visiting Dr. Rajwa Jbeily, Deputy Minister of the Syrian Ministry of Healt2011/9/29
-
Novartis files for European Marketing Authorisation for Seebri BreezhalerNovartis has filed for European marketing authorisation of its chronic obstructive pulmonary disease treatment, Seebri Breezhaler. The filing follows new Phase III data, presented by Novartis at the2011/9/29
-
SFDA further specifies relevant requirements on record filing and change of authorized registration responsible agent in China for administrative licensing of imported cosmeticsThe State Food and Drug Administration (SFDA) recently issued a notice to further specify relevant requirements on record filing and change of authorized registration responsible agent in China for ad2011/9/28
-
SFDA further specifies requirements for application documents of cosmetics administrative licensingIn order to further standardize the application of cosmetics administrative licensing, the State Food and Drug Administration (SFDA) recently issued a notice, which further specified relevant requirem2011/9/28